Citation: Ruoxi Li, Dazheng Ling, Tongke Tang, Zhenghui Huang, Manjiong Wang, Fei Mao, Jin Zhu, Lubin Jiang, Jian Li, Xiaokang Li. Repurposing of antitumor drug candidate Quisinostat lead to novel spirocyclic antimalarial agents[J]. Chinese Chemical Letters, ;2021, 32(5): 1660-1664. doi: 10.1016/j.cclet.2020.12.023 shu

Repurposing of antitumor drug candidate Quisinostat lead to novel spirocyclic antimalarial agents

Ruoxi Li ^{a, 1} ,
Dazheng Ling ^{a, 1} ,
Tongke Tang ^{b, e, 1} ,
Zhenghui Huang ^b ,
Manjiong Wang ^a ,
Fei Mao ^a ,
Jin Zhu ^a ,
Lubin Jiang ^{b, e, **,} ,
Jian Li ^{a, c, d, *,} ,
Xiaokang Li ^{a, ***,}

a.
State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
b.
Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China
c.
College of Pharmacy and Chemistry, Dali University, Dali 671000, China
d.
Frontiers Science Center for Materiobiology and Dynamic Chemistry, East China University of Science and Technology, Shanghai 200237, China
e.
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China

^**

^***

lbjiang@ips.ac.cn

jianli@ecust.edu.cn

xkli@ecust.edu.cn

Received Date: 1 November 2020
Revised Date: 26 November 2020
Accepted Date: 13 December 2020
Available Online: 20 December 2020

Figures(3)

Antimalarial chemotherapies endowed with effectiveness against drug-resistant parasites and good safety are urgently required in clinical. Our previous research revealed that clinical phase Ⅱ antitumor drug Quisinostat was a promising antimalarial prototype by inhibiting the activity of Plasmodium falciparum (P. falciparum) histone deacetylase (PfHDAC). Herein, 30 novel spirocyclic linker derivatives were designed and synthesized based on Quisinostat as lead compound, and then their antimalarial activities and cytotoxicity were systematically evaluated. Among them, compounds 8 and 27 could effectively eliminate wild-type and multi-drug resistant P. falciparum parasites, and display weakened cytotoxicity and good metabolic stability. Western blot assay demonstrated that they could inhibit PfHDAC activity like Quisinostat. In addition, both 8 and 27 showed certain antimalarial efficacy in rodent malaria model, and the animal toxicity of 8 was significantly improved compared with Quisinostat. Overall, 8 and 27 were structurally novel PfHDAC inhibitors and provided prospective prototype for further antimalarial drug research.
- Malaria,
- PfHDAC inhibitor,
- Drug repurposing,
- Epigenetic modulator,
- Erythrocytic therapy
1. [1]
  World Health Organization, World Malaria Report, 2019. https://apps.who.int/iris/handle/10665/330011.
2. [2]
  J.N. Burrows, E. Burlot, B. Campo, et al., Parasitology 141(2014) 128-139. doi: 10.1017/S0031182013000826
3. [3]
  World Health Organization, Guidelines for the Treatment of Malaria, 3rd. ed., (2015). https://www.who.int/docs/default-source/documents/publications/gmp/guidelines-for-the-treatment-of-malaria-eng.pdf.
4. [4]
  I.B. Müller, J.E. Hyde, Future Microbiol. 5(2010) 1857-1873. doi: 10.2217/fmb.10.136
5. [5]
  B. Blasco, D. Leroy, D.A. Fidock, Nat. Med. 23(2017) 917-928. doi: 10.1038/nm.4381
6. [6]
  D. Menard, A. Dondorp, Cold Spring Harb. Perspect. Med. 7(2017) a025619. doi: 10.1101/cshperspect.a025619
7. [7]
  L. Zhu, J. Tripathi, F.M. Rocamora, et al., Nat. Commun. 9(2018) 5158. doi: 10.1038/s41467-018-07588-x
8. [8]
  J. Wang, C. Xu, F.L. Liao, et al., N. Engl. J. Med. 380(2019) 2087-2089. doi: 10.1056/NEJMp1901233
9. [9]
  A.M. Talman, J. Clain, R. Duval, R. Ménard, F. Ariey, Trends Parasitol. 35(2019) 953-963. doi: 10.1016/j.pt.2019.09.005
10. [10]
  World Health Organization, Status Report on Artemisinin Resistance and ACT Efficacy, December, 209. https://www.who.int/docs/default-source/documents/publications/gmp/who-cds-gmp-2019-17-eng.pdf.
11. [11]
  A. Uwimana, E. Legrand, B.H. Stokes, et al., Nat. Med. 26(2020) 1602-1608. doi: 10.1038/s41591-020-1005-2
12. [12]
  G.S. Hailu, D. Robaa, M. Forgione, et al., J. Med. Chem. 60(2017) 4780-4804. doi: 10.1021/acs.jmedchem.6b01595
13. [13]
  K.T. Andrews, A. Haque, M.K. Jones, Immunol. Cell Biol. 90(2012) 66-77. doi: 10.1038/icb.2011.97
14. [14]
  K.T. Andrews, T.N. Tran, D.P. Fairlie, Curr. Pharm. Design 18(2012) 3467-3479.
15. [15]
  R. Fioravanti, N. Mautone, A. Rovere, D. Rotili, A. Mai, Curr. Opin. Chem. Biol. 57(2020) 65-74. doi: 10.1016/j.cbpa.2020.05.008
16. [16]
  S.J. Darkin-Rattray, A.M. Gurnett, R.W. Myers, et al., Proc. Natl. Acad. Sci. U. S. A. 93(1996) 13143-13147. doi: 10.1073/pnas.93.23.13143
17. [17]
  L.B. Jiang, Z.H. Huang, WO2017143964, 2017.
18. [18]
  Z.H. Huang, R.X. Li, T.K. Tang, et al., Cell Discov. (2020), doi:http://dx.doi.org/10.1038/s41421-020-00215-4. doi: 10.1038/s41421-020-00215-4
19. [19]
  J.W.J. Dickens, I.N. Houpis, Y.L. Lang, et al., WO2008138918 November 20, (2008).
20. [20]
  Y. Yang, Y. Yu, X. Li, et al., J. Med. Chem. 60(2017) 1994-2005. doi: 10.1021/acs.jmedchem.6b01733
21. [21]
  M.B. Jimenez-Diaz, T. Mulet, S. Viera, et al., Antimicrob. Agents Chemother. 53(2009) 4533-4536. doi: 10.1128/AAC.00519-09
22. [22]
  T. Ono, T. Tadakuma, A. Rodriguez, Exp. Parasitol. 115(2007) 310-313. doi: 10.1016/j.exppara.2006.09.008
1. [1]
  Zhenxing Li , Yue Ding , Xinxin Tuo , Jinhong Hu , Taihong Zhang , Xiang Zhou , Liwei Liu , Song Yang . Structure-based drug repurposing targeting pathogenic virus superfamily 1 helicase: An integrated multi-computational screening and bioactivity identification strategy. Chinese Chemical Letters, 2025, 36(9): 110737-. doi: 10.1016/j.cclet.2024.110737
2. [2]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929
3. [3]
  Lei Shen , Hongmei Liu , Ming Jin , Jinchao Zhang , Caixia Yin , Shuxiang Wang , Yutao Yang . “Three-in-one” strategy of trifluoromethyl regulated blood-brain barrier permeable fluorescent probe for peroxynitrite and antiepileptic evaluation of edaravone. Chinese Chemical Letters, 2024, 35(10): 109572-. doi: 10.1016/j.cclet.2024.109572
4. [4]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
5. [5]
  Jing Feng , Yanhong Liu , Liming Gong , Chenfei Liu , Congcong Xiao , Liqing Chen , Mingji Jin , Zhonggao Gao , Wei Huang , Yubo Li . Recent progress on drug delivery systems of regulating intratumoral bacteria for tumor therapy. Chinese Chemical Letters, 2025, 36(11): 110907-. doi: 10.1016/j.cclet.2025.110907
6. [6]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
7. [7]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
8. [8]
  Chenshi Lin , Chao Teng , Bingbing Li , Wei He . Anti-inflammatory drug-assisted microRNA gene therapy for effectively improving pulmonary hemodynamics. Chinese Chemical Letters, 2025, 36(7): 110450-. doi: 10.1016/j.cclet.2024.110450
9. [9]
  Jiawei Zhu , Yucheng Xiong , Xiaoxue Bai , Chenlong Xie , Baichen Xiong , Yao Chen , Haopeng Sun . Small molecule-drug conjugates: Mechanistic insights and strategic design for enhanced cancer therapy. Chinese Chemical Letters, 2025, 36(10): 110799-. doi: 10.1016/j.cclet.2024.110799
10. [10]
  Min Zhang , Ye Chen , Yanan Li , Yifan Zhao , Bai Lv , Jie Cao , Bing Yu , Hailin Cong . Manipulating extracellular matrix to enhance intratumor drug delivery for nanomaterial-based photothermal therapy. Chinese Chemical Letters, 2025, 36(12): 111588-. doi: 10.1016/j.cclet.2025.111588
11. [11]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
12. [12]
  Mingrui Zhang , Lingyu Jin , Yuda Zhu , Junfeng Kou , Bo Liu , Jing Chen , Xiaolin Zhong , Xianghua Wu , Junfeng Zhang , Wenxiu Ren . A near-infrared Ⅱ fluorescent dye based on oxanthracene: Real-time imaging of drug-induced acute liver injury and photothermal therapy for tumor. Chinese Chemical Letters, 2025, 36(10): 110772-. doi: 10.1016/j.cclet.2024.110772
13. [13]
  Shu-Yi Gu , Tian Feng , Fang-Yin Gang , Si-Yu Yu , Wan Chan , Zhao-Cheng Ma , Yao-Hua Gu , Bi-Feng Yuan . Persistent organic pollutant perfluorooctanoic acid induces alterations in epigenetic modifications of DNA and RNA. Chinese Chemical Letters, 2025, 36(12): 110957-. doi: 10.1016/j.cclet.2025.110957
14. [14]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
15. [15]
  Jia Chen , Yun Liu , Zerong Long , Yan Li , Hongdeng Qiu . Colorimetric detection of α-glucosidase activity using Ni-CeO₂ nanorods and its application to potential natural inhibitor screening. Chinese Chemical Letters, 2024, 35(9): 109463-. doi: 10.1016/j.cclet.2023.109463
16. [16]
  Chao Chen , Wenwen Yu , Guangen Huang , Xuelian Ren , Xiangli Chen , Yixin Li , Shenggui Liang , Mengmeng Xu , Mingyue Zheng , Yaxi Yang , He Huang , Wei Tang , Bing Zhou . Asymmetric macrocyclization enabled by Rh(Ⅲ)-catalyzed CH activation: Enantioenriched macrocyclic inhibitor of Zika virus infection. Chinese Chemical Letters, 2024, 35(11): 109574-. doi: 10.1016/j.cclet.2024.109574
17. [17]
  Zhexin Chen , Yuqing Shi , Fang Zhong , Kai Zhang , Furong Zhang , Shenghong Xie , Zhongbin Cheng , Qian Zhou , Yi-You Huang , Hai-Bin Luo . Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects. Chinese Chemical Letters, 2025, 36(4): 109956-. doi: 10.1016/j.cclet.2024.109956
18. [18]
  Chanqi Ye , Jia Zhang , Jie Shen , Ruyin Chen , Qiong Li , Peng Zhao , Dong Chen , Jian Ruan . Attractive Pickering emulsion gel loaded with oxaliplatin and lactate dehydrogenase inhibitor increases the anti-tumor effect in hepatocellular carcinoma. Chinese Chemical Letters, 2025, 36(7): 110519-. doi: 10.1016/j.cclet.2024.110519
19. [19]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
20. [20]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335

Get Citation

PDF

XML

Metrics

PDF Downloads(5)
Abstract views(1510)
HTML views(137)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142